Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

PROGRESS ON THE INCLUSION OF INNOVATIVE MEDICINES IN THE 2026 NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that one new indication of Ameile and two new indications of XINYUE, both being innovative medicines of the Group, have been successfully added to the new National Reimbursement Drug List (2026 Version) (the "**2026 NRDL**"). The new NRDL will be officially implemented on January 1, 2027.

1. One new indication of Aumolertinib Mesylate Tablets (trade name: Ameile 阿美樂®), approved in January 2026, has been added to the 2026 NRDL:

    - Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

2. Two new indications of Inebilizumab Injection (trade name: XINYUE 昕越®), approved in August 2025 and March 2026, have been added to the 2026 NRDL:

    - for immunoglobulin G4-related disease (IgG4-RD) in adult patients.

    - used in combination with conventional therapeutic drugs for the treatment of adult patients with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

In addition to the aforementioned inclusion, the remaining four indications of Aumolertinib Mesylate Tablets (trade name: Ameile 阿美樂®), the remaining one indication of Inebilizumab Injection (trade name: XINYUE 昕越®) and Flumatinib Mesylate Tablets (trade name: Hansoh Xinfu 豪森昕福®) have been renewed in the 2026 NRDL. Polyethylene Glycol Loxenatide Injection (trade name: Fulaimei 孚來美®) has also been renewed in the 2026 NRDL and its scope of medical insurance payment has been expanded. Pegmolesatide Injection (trade name: Saint Luolai 聖羅萊®) and Tenofovir Amibufenamide Tablets (trade name: Hengmu 恒沐®) are currently within the term of NRDL agreement, with the agreement valid until December 31, 2027. Morinidazole and Sodium Chloride Injection (trade name: Mailingda 邁靈達®) has been included in category B of general list of the NRDL. All approved indications of the Group's marketed innovative medicines are included in the NRDL, which helps to further improve the affordability and accessibility of the respective innovative medicines among patients.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, November 15, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.